fda’s clinical regulatory perspective: designing first-in-human trial for cellular and gene therapy
Published 3 years ago • 6.6K plays • Length 36:56Download video MP4
Download video MP3
Similar videos
-
37:34
designing first-in-human trials for small molecules and biologics
-
46:52
preclinical considerations for cell and gene therapy products, an fda perspective
-
31:53
getting to first-in-human for small molecules and biologics
-
56:31
cmc considerations for biotechnology product development: a regulatory perspective
-
22:36
regulatory considerations for cell and gene therapies - jim dekloe
-
29:42
cmc considerations for car t cell product development
-
1:10:23
fda clinical investigator training course (citc) 2022, day 1 – part 3
-
8:21
60 degrees pharmaceuticals reports doubling of q2 2024 revenues and advances clinical trials
-
43:14
introduction to regulatory science at the fda
-
1:57
fda accepts application for possible first gene therapy for genetic disease in us
-
17:45
understanding the fda approval process for gene therapies: step-by-step explanation
-
2:33
boy 1st in ny to receive fda-approved gene therapy for blood disorder
-
17:14
real-world challenge: establishing the value of gene therapy for patients
-
16:25
fda’s efforts to advance the development and approval of cellular and gene therapies
-
3:17
a new fda-approved gene therapy helps treat a rare childhood cancer
-
20:06
non-clinical evaluation of immunogenicity risk of generic complex peptide products
-
37:46
clinical pharmacology regulatory sciences in drug development and precision medicine
-
52:35
chardan kol call: regulatory perspective - cmc for cell and gene therapy
-
59:19
understanding us fda regulatory responsibilities for cell therapy companies